Literature DB >> 31253858

T2DM treatment trial results.

Claire Greenhill1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31253858     DOI: 10.1038/s41574-019-0234-2

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  5 in total

1.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Authors:  Ofri Mosenzon; Stephen D Wiviott; Avivit Cahn; Aliza Rozenberg; Ilan Yanuv; Erica L Goodrich; Sabina A Murphy; Hiddo J L Heerspink; Thomas A Zelniker; Jamie P Dwyer; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Eri T Kato; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna Maria Langkilde; Marc S Sabatine; Itamar Raz
Journal:  Lancet Diabetes Endocrinol       Date:  2019-06-10       Impact factor: 32.069

2.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Mansoor Husain; Andreas L Birkenfeld; Morten Donsmark; Kathleen Dungan; Freddy G Eliaschewitz; Denise R Franco; Ole K Jeppesen; Ildiko Lingvay; Ofri Mosenzon; Sue D Pedersen; Cees J Tack; Mette Thomsen; Tina Vilsbøll; Mark L Warren; Stephen C Bain
Journal:  N Engl J Med       Date:  2019-06-11       Impact factor: 91.245

3.  Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.

Authors:  Thomas R Pieber; Bruce Bode; Ann Mertens; Young Min Cho; Erik Christiansen; Christin L Hertz; Signe O R Wallenstein; John B Buse
Journal:  Lancet Diabetes Endocrinol       Date:  2019-06-09       Impact factor: 32.069

4.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Jeffrey S Riesmeyer; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.